NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Interna Therapeutics

Interna Therapeutics

Private
IsraelHealthcare & Life Scienceshttps://interna.bio/

Last Round

Early Funding

Nov 4, 2024

Total Funding Raised

$10.25M

Company Overview

Interna Therapeutics is a biotechnology company that develops a universal intracellular delivery platform based on its proprietary Molecular Nano Motor (MNM) technology for the delivery of macromolecule drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

intracellular deliverydrug delivery platformMolecular Nano-MotorsMNMbiopharmaceuticalsiRNA deliverydrug delivery techmacromolecule deliveryintranasal drug deliverybiotech licensingrespiratory viral therapydrug delivery startupbiotech platformclinical-stage biotechtherapeutic delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Interna Therapeutics Comparables

Compare Interna Therapeutics with similar companies based on industry and business-model similarity.

Interna Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CyGenica
85%
Sapreme Technologies BV
83%
Permeasis Therapeutics
80%

Interna Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingNov 4, 2024

Key People

Founding team and executive leadership

Yuval Gottenstein

Chief Executive Officer

Executive Team

Etty Genis

Chief Financial Officer, VP Finance & COO, Acting CFO

Executive Team

Guy Kornberg

Chief Operating Officer

Executive Team

Interna Therapeutics Investors

Notable investors and investment history

Interna Therapeutics investors
InvestorRounds
Gates FoundationEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 3, 2026

    Monthly visitors grew 169% MoM, reaching 2.8K.

Interna Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Interna Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Interna Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersIsrael
Employee Range18
Year Founded1996
Last FundingNov 4, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.